Материал: guidelines_atherosclerosis_2020
Journal of ATHEROSCLEROSIS AND DYSLIPIDEMIAS
Журнал Национального общества по изучению атеросклероза Official Journal of the Russian National Atherosclerosis Society
ISSN 2219-8202
В номере
Рекомендации
Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотра
|
|
Репринт |
|
|
|
www.noatero.ru |
2020 |
№ 1 |
|
|
|
Репринт подготовлен при поддержке компании «Эбботт»
ISSN 2219–8202
АТЕРОСКЛЕРОЗ и ДИСЛИПИДЕМИИ (АиД) www.noatero.ru
Печатный орган Национального общества по изучению атеросклероза Выпускается с 2010 года Подписной индекс 90913
Журнал включен в перечень рецензируемых научных журналов и изданий ВАК
№ 1 (38) 2020
Главный редактор |
|
|
|
|
|
|
|
|
Редакционный совет |
|
|
|
|
|
|
|
|
|
|
В. В. Кухарчук (Москва)
Заместители главного редактора
Ю.П. Никитин (Новосибирск)
Г.Г. Арабидзе (Москва)
Научные редакторы
А. А. Лякишев (Москва)
Е. В. Меркулов (Москва)
А. Б. Сумароков (Москва)
Ответственный секретарь
Н.Б. Горнякова (Москва)
Редакционная коллегия
А.А. Аншелес (Москва)
О.И. Афанасьева (Москва) С. А. Бойцов (Москва)
М. Г. Бубнова (Москва) И. Е. Чазова (Москва) М.В. Ежов (Москва) Ю. А. Карпов (Москва)
Г. А. Коновалов (Москва)
В. О. Константинов
(Санкт-Петербург)
П. П. Малышев (Москва)
А.И. Мартынов (Москва) С. Н. Покровский (Москва) Д. И. Садыкова (Казань)
А.Н. Самко (Москва)
И.В. Сергиенко (Москва)
В. В. Скибицкий (Краснодар) А. А. Ширяев (Москва)
А.А. Абдуллаев (Махачкала)
Ф. Бартер (Австралия)
М. Враблик (Чехия)
А.С. Галявич (Казань)
В.С. Гуревич (Санкт-Петербург)
И. В. Дворяшина (Архангельск) А. А. Демидов (Астрахань)
О.М. Драпкина (Москва)
С. Я. Ерегин (Ярославль)
Н. Э. Закирова (Уфа) Р. С. Карпов (Томск)
Н. А. Козиолова (Пермь)
П. Лансберг (Нидерланды)
И. В. Логачева (Ижевск) Ю. М. Лопатин (Волгоград)
О. Ш. Ойноткинова (Москва)
В.Э. Олейников (Пенза)
Ю. М. Поздняков (Московская обл.)
А. И. Попугаев (Вологда)
Р. И. Сайфутдинов (Оренбург) М. С. Сафарова (Москва)
А. Е. Семенова (Москва)
В.В. Симерзин (Самара)
В.Н. Смирнов (Москва)
О. Г. Смоленская (Екатеринбург)
Т. В. Тюрина (Санкт-Петербург) К. Ховинг (Нидерланды)
Л. А. Хаишева (Ростов-на-Дону)
С.В. Шалаев (Тюмень)
С.В. Шлык (Ростов-на-Дону)
С.С. Якушин (Рязань)
Редакция: |
Электронная версия журнала доступна на сайте НОА (www.noatero.ru) и на сайте |
|
Российский кардиологический |
Научной электронной библиотеки (www.elibrary.ru) |
|
научно-производственный комплекс, |
Правила для авторов: www.noatero.ru |
|
отдел атеросклероза |
||
|
||
121552, Россия, Москва, |
Полная или частичная публикация материалов, размещенных в журнале |
|
ул. 3-я Черепковская, 15а |
или на сайте, допускается только с письменного разрешения редакции |
|
Тел.:+7 (495) 414–72–86 |
Ответственность за достоверность рекламных публикаций несет рекламодатель |
|
e-mail: JAD_cardio@mail.ru, |
||
|
||
igorcardio@mail.ru |
Свидетельство о регистрации ПИ № ФС 77–39935 от 20.05.2010 |
|
Факс:+7 (495) 414–60–68 |
||
Периодичность– 4 раза в год. Тираж– 3000 экземпляров |
||
Издательство: |
||
|
||
ООО «ПатиСС» |
Все права защищены. © 2010 «ПатиСС» |
|
Тел.: +7 (499) 372–51–82 |
|
|
e-mail: info@patiss.ru |
|
ISSN 2219–8202
Journal of ATHEROSCLEROSIS AND DYSLIPIDAEMIAS (JAD)
www.noatero.ru
Official Journal of the Russian National Atherosclerosis Society (RNAS)
Founded in 2010
Subscription index 90913
The Journal is included in the List of scientific journals and publications of the Higher Attestation
Commission (VAK)
№ 1 (38) 2020
Editor-in-Chief
V. V. Kukharchuk (Moscow)
Deputy Editors
Y.P. Nikitin (Novosibirsk)
G.G. Arabidze (Moscow)
Senior Editors
A. А. Lyakishev (Moscow)
E. V. Merkulov (Moscow)
A. B. Sumarokov (Moscow)
Executive Secretary
N.B. Gornyakova (Moscow)
Associate Editors
A. A. Ansheles (Moscow) |
P. P. Malyshev (Moscow) |
O.I. Afanasyeva (Moscow) |
A. I. Martynov (Moscow) |
S.A. Boytsov (Moscow) |
S. N. Pokrovskii (Moscow) |
M.G. Bubnova (Moscow) |
D. I. Sadykova (Kazan) |
I.E. Chazova (Moscow) |
A. N. Samko (Moscow) |
M.V.Ezhov (Moscow) |
I.V. Sergienko (Moscow) |
Y.A. Karpov (Moscow) |
V. V. Skibitskii (Krasnodar) |
G. A. Konovalov (Moscow) |
A. A. Shiryaev (Moscow) |
V. O. Konstantinov |
|
(Saint Petersburg) |
|
Editorial Board
A.A. Abdullaev (Makhachkala)
P.Barter (Australia)
A.A. Demidov (Astrakhan)
O. M. Drapkina (Moscow)
I. V. Dvoriashina (Arkhangelsk)
S.Ya. Eregin (Yaroslavl)
A.S. Galyavich (Kazan)
V.S. Gurevich (Saint Petersburg)
K.Hovingh (Netherlands)
R.S. Karpov (Tomsk)
L.A. Khaisheva (Rostov-on-Don)
N.A. Koziolova (Perm)
P.J. Lansberg (Netherlands)
I.V. Logacheva (Izhevsk)
Y.M. Lopatin (Volgograd)
O.Sh. Oinotkinova (Moscow)
V.E. Oleynikov (Penza)
A.I. Popugaev (Vologda)
Y.M. Pozdnyakov (Moscow region)
M.S. Safarova (Moscow)
R.I. Sayfutdinov (Orenburg)
A.E. Semenova (Moscow)
S.V. Shalaev (Tyumen)
S.V. Shlyk (Rostov-on-Don)
V.V. Simerzin (Samara)
V.N. Smirnov (Moscow)
O.G. Smolenskaya (Ekaterinburg)
T.V. Tyurina (Saint Petersburg)
M.Vrablik (Czech Republic)
S.S. Yakushin (Ryazan)
N.E. Zakirova (Ufa)
Editorial office:
Russian Cardiology Research Complex, Atherosclerosis Department
15a, 3-rd Cherepkovskaya St, 121552, Moscow, Russia Tel:+7 (495) 414–72–86 e-mail: JAD_cardio@mail.ru, igorcardio@mail.ru
Fax:+7 (495) 414–60–68
Publishing house:
LLC "PatiSS"
Tel:+7 (499) 372–51–82 e-mail: info@patiss.ru
Electronic version is available on the website of RNAS (www.noatero.ru) and within the Russian Science Citation Index (www.elibrary.ru)
Instructions for Authors: www.noatero.ru
Permission should be obtained from the publisher to re-use materials of the Journal. Publication of the materials placed in the journal or website is allowed only with the written permission of the editors
Although all advertising materials is expected to conform to ethical and medical standards, inclusion in this publication does not constitute a guarantee or endorsement of the mentioned products or claims made of it by its manufacturer
Mass media registration certificate ПИ № ФС 77–39935 dated 20.05.2010
The periodicity is 4 issues per year. The circulation is 3000 copies
All rights reserved. © 2010 "PatiSS"
Cодержание |
|
|
|
. |
|
, VII ............................................................................................................................................ |
5 |
................................................................................................................................................................................ |
6 |
• ...................................................................................................................................................................................................... |
7 |
• ............................................................................................................................................................ |
7 |
....................................................................................................................................................................... |
8 |
• • -•• • ....................................................................................................... |
8 |
- SCORE ............................................................................................................ |
10 |
- ...................................................................................................................................... |
10 |
- .................. |
13 |
• • • ................................................................................................ |
14 |
.................................................................................................................................... |
16 |
• ...................................................................................................................................................... |
16 |
• ...................................................................................................................... |
20 |
• • • ............................................................................................................................... |
21 |
- •• • ..................................................................................................... |
23 |
• .............................................................................................................................................................................. |
23 |
• • • ................................................................................................................................................... |
24 |
................................................................................................................... |
24 |
e .......................................................................................................................... |
26 |
.......................................................................................................................................................... |
26 |
• • ................................................................................................................................................ |
26 |
• • .............................................................................................................................................. |
26 |
• • ................ |
28 |
• • ................................................................................................................................. |
29 |
• €• .......................................................... |
29 |
‚ .............................................................................................................................................................................................. |
31 |
• ................................................................................................................................................................................ |
32 |
ƒ• • • ........................................................................................................................................................................ |
38 |
Contents |
|
Guidelines |
|
Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. |
|
Russian recommendations VII revision ....................................................................................................................................................... |
5 |
List of abbreviations ................................................................................................................................................................ |
6 |
Introduction ............................................................................................................................................................................ |
7 |
Classi„cation of dyslipidemia ................................................................................................................................................. |
7 |
Screening for dyslipidemia ..................................................................................................................................................... |
8 |
Assessment of the risk of cardiovascular complications ........................................................................................................ |
8 |
Assessment of cardiovascular risk on a scale of SCORE ..................................................................................................... |
10 |
Categories of cardiovascular risk ................................................................................................................................ |
10 |
e role of non-invasive imaging techniques in assessing the overall risk of cardiovascular disease ................................ |
13 |
Correction of risk factors for atherosclerosis and complications ........................................................................................ |
14 |
Drug therapy of dyslipidemia ............................................................................................................................................... |
16 |
erapy of hypercholesterolemia ...................................................................................................................................... |
16 |
Residual risk and association with triglycerides ............................................................................................................... |
20 |
Approaches to the treatment of hypertriglyceridemia and atherogenic dyslipidemia ....................................................... |
21 |
Treatment of dyslipidemia in certain categories of patients ................................................................................................ |
23 |
Diabetes ........................................................................................................................................................................... |
23 |
Familial hypercholesterolemia .......................................................................................................................................... |
24 |
Drug treatment of familial hyperlipidemia in adults ................................................................................................ |
24 |
Drug treatment of children with familial hyperlipidemia .......................................................................................... |
26 |
Apheresis of lipoproteins .......................................................................................................................................... |
26 |
erapy of dyslipidemia in women ................................................................................................................................... |
26 |
erapy of dyslipidemia in the elderly patients ................................................................................................................ |
26 |
Patients with acute coronary syndrome and candidates for percutaneous coronary interventions ................................... |
28 |
Patients with chronic kidney disease ................................................................................................................................ |
29 |
Monitoring the e…cacy and tolerance of lipid-lowering therapy ........................................................................................ |
29 |
Conclusion ............................................................................................................................................................................. |
31 |
List of references ................................................................................................................................................................... |
32 |
Instructions for authors ............................................................................................................................................................................ |
38 |